Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Michael Thompson

Hematology & Oncology Summit, WI Medical Doctor

NPI 1265453070 CMS profile 192826

36500 Aurora Dr, Summit, WI 53066

Open in the dashboard

General payments

$96,379

32 records reported · program years 2019–2022

Research payments

$7,653

Paid to them · 3 records reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$378,143 paid to institutions, not to them · program years 2019–2023

Through program year 2022, Michael Thompson of Summit, WI is reported in the CMS Open Payments database as having received $96,379 across 32 general payments and $7,653 in research payments paid to them. Separately, studies naming them as principal investigator received $378,143 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $13,643 4
2021 General $22,538 9
2020 General $24,354 7
2020 Research $4,200 1
2019 General $35,845 12
2019 Research $3,453 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Thompson
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Michael Thompson were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Michael Thompson Hematology & Oncology median Middle half National median
2019 $35,845 $529 $121–$2,516 $163
2020 $24,354 $339 $82–$2,213 $114
2021 $22,538 $263 $49–$1,965 $132
2022 $13,643 $416 $103–$2,395 $149
2023 $0 $542 $125–$2,646 $160
2024 $0 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Takeda Pharmaceuticals U.S.A., Inc. $78,820 23 payments
  2. AbbVie, Inc. $4,200 1 payment
  3. Epizyme, Inc., $4,050 2 payments
  4. Genzyme Corporation $3,500 1 payment
  5. Adaptive Biotechnologies Corporation $2,900 1 payment
  6. Janssen Biotech, Inc. $1,768 1 payment
  7. E.R. Squibb & Sons, L.L.C. $1,000 1 payment
  8. Osiris Therapeutics Inc. $119 1 payment
  9. Ferring Pharmaceuticals Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Consulting Fee $73,938 14 payments
  2. Travel and Lodging $16,702 9 payments
  3. Honoraria $4,050 2 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $1,000 1 payment
  5. Food and Beverage $690 6 payments
Products named General payments · program years 2019–2022
  1. NINLARO $35,151 12 payments
  2. VENCLEXTA $4,200 1 payment
  3. TAZVERIK $4,050 2 payments
  4. SARCLISA $3,500 1 payment
  5. clonoSEQ $2,900 1 payment
  6. DARZALEX $1,768 1 payment
  7. GRAFIX $119 1 payment
  8. Stravix $119 1 payment
  9. GrafixPL $119 1 payment
  10. CLENPIQ $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2022
  1. AbbVie, Inc. $4,200 1 payment
  2. Celgene Corporation $3,342 1 payment
  3. Eli Lilly and Company $111 1 payment

Records

35 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record